» Articles » PMID: 22981677

Effects of Mirabegron, a Novel β3-adrenoceptor Agonist, on Primary Bladder Afferent Activity and Bladder Microcontractions in Rats Compared with the Effects of Oxybutynin

Overview
Journal Eur Urol
Specialty Urology
Date 2012 Sep 18
PMID 22981677
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder.

Objective: The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin.

Design, Setting, And Participants: Female Sprague-Dawley rats were anesthetized. The SAAs generated from left L6 dorsal roots were identified by electrical stimulation of the left pelvic nerve and bladder distension. Nerves with conduction velocities (CVs) >2.5 m/s were designated as Aδ-fibers, and nerves with CVs<2.5 m/s were designated as C-fibers.

Outcome Measurements And Statistical Analysis: Two measurements were performed in separate animals. First, after measuring the baselines of SAA during constant filling cystometry, the procedure was repeated with each intravenous administration of mirabegron at three doses-0.1, 0.3, and 1.0mg/kg-cumulatively. Second, the bladder was filled with saline until the intravesical pressure reached 30 cm H(2)O and was kept under an isovolumetric condition; then the recording was performed for 5 min with vehicle and mirabegron or oxybutynin administrated intravenously.

Results And Limitations: A total of 74 single-unit afferent fibers were isolated from 55 rats (Aδ-fibers: n=34; C-fibers: n=40). SAAs of both Aδ-fibers and C-fibers in response to bladder filling significantly decreased after mirabegron administration in a dose-dependent manner, which was more remarkable for Aδ-fibers. During an isovolumetric condition of the bladder, the mean bladder pressure and the number of microcontractions decreased after mirabegron administration, whereas these parameters did not change with oxybutynin administration. SAAs of Aδ-fibers were significantly decreased by mirabegron administration at both 0.3 and 1mg/kg, whereas SAAs of C-fibers decreased only at 1mg/kg. In contrast, oxybutynin (1mg/kg) did not alter either type of SAA.

Conclusions: The present study demonstrates that mirabegron can inhibit mechanosensitive bladder afferent activity, especially of Aδ-fibers, which may be related to suppression of bladder microcontractions.

Citing Articles

Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives.

Kwon J, Kim D, Cho K, Hashimoto M, Matsuoka K, Kamijo T Int Neurourol J. 2024; 28(Suppl 1):12-33.

PMID: 38461853 PMC: 10932578. DOI: 10.5213/inj.2448002.001.


Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women.

Liang C, Hsieh W, Lo T, Huang T, Chou Y, Huang J Sci Rep. 2023; 13(1):19368.

PMID: 37938600 PMC: 10632490. DOI: 10.1038/s41598-023-46786-6.


Male Akita mice develop signs of bladder underactivity independent of NLRP3 as a result of a decrease in neurotransmitter release from efferent neurons.

Hughes Jr F, Allkanjari A, Odom M, Mulcrone J, Jin H, Purves J Am J Physiol Renal Physiol. 2023; 325(1):F61-F72.

PMID: 37167271 PMC: 10292983. DOI: 10.1152/ajprenal.00284.2022.


Mirabegron in the Management of Overactive Bladder Syndrome.

OKane M, Robinson D, Cardozo L, Wagg A, Abrams P Int J Womens Health. 2022; 14:1337-1350.

PMID: 36147890 PMC: 9487925. DOI: 10.2147/IJWH.S372597.


Role of PTHrP in attenuating transient pressure rises and associated afferent nerve activity of the rat bladder.

Sugiura A, Mitsui R, Hashitani H Pflugers Arch. 2022; 474(10):1077-1090.

PMID: 35907965 DOI: 10.1007/s00424-022-02736-1.